NHS cancer patients are denied new drug
5/14/2007 London, England staff Telegraph.co.uk Patients suffering from head and neck cancer are to be denied a new drug on the National Health Service because it is claimed it is no more effective than existing drugs. The National Institute for Health and Clinical Excellence (Nice) has rejected Erbitux, also known as cetuximab, for cancer sufferers in England and Wales. The drug is available in Scotland. Nice said the drug, when used in conjunction with radiotherapy, did not offer "better therapeutic value" than existing treatments for locally advanced head and neck cancer. However, according to clinical trials carried out by Merck Serono UK, the drug's manufacturer, patients treated with Erbitux plus radiotherapy survive for an average of 49 months, compared with 29 months for those treated with radiotherapy alone. Campaigners said the move was a blow to patients as the drug is the first licensed in the past 40 years for treating locally advanced head and neck cancer. Andrew Dillon, the chief executive of Nice, said: "The evidence presented to the independent advisory committee did not persuade them that cetuximab works any better or offers better therapeutic value than existing treatments for head and neck cancer. "Sometimes it is possible for the committee to identify a subgroup of patients in whom a drug would be effective, for example, patients for whom other treatments are not suitable. "The committee did consider whether there are any subgroups of patients for whom cetuximab could be clinically and cost effective but they were not presented [...]